Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib plus induction chemotherapy for pediatric relapsed or refractory acute lymphoblastic leukemia
NL-OMON56393Phase 2Not yet recruiting
- Sponsor
- Amgen
- Start
- Jul 2023
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of carfilzomib in acute lymphoblastic leukemia (ALL) (5 arms), sponsored by Amgen. Primary endpoints: Safety and tolerability, Maximum tolerated dose and 1 more. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
carfilzomib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON56393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56393.